Trial Profile
Safety and efficacy of sorafenib, erlotinib and gemcitabine in patients with non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.